Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Latest Information Update: 13 Mar 2025
At a glance
- Drugs Olaparib (Primary) ; Patritumab Deruxtecan (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ICARUSBREAST02
Most Recent Events
- 13 Dec 2024 Trial design presented at the 47th Annual San Antonio Breast Cancer Symposium.
- 02 Dec 2024 According to a Daiichi Sankyo Company media release, data from this study will be presented in a Poster presentation on Wednesday, December 11, 5:30 - 7:00 pm, at San Antonio Breast Cancer Symposium (#SABCS24).
- 28 Mar 2024 Status changed from not yet recruiting to recruiting.